China Universal Asset Management Co., Ltd. Intercept Pharmaceuticals, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$9.99 - $18.71 $5,234 - $9,804	524 Added 95.8%	1,071 $19,000
Q3 2023 Oct 30, 2023	BUY	$9.99 - $18.71 $5,234 - $9,804	524 Added 95.8%	1,071 $20,000
Q2 2023 May 21, 2024	SELL	$9.17 - $19.29 $128 - $270	-14 Reduced 2.5%	547 $6,000
Q2 2023 Jul 27, 2023	SELL	$9.17 - $19.29 $128 - $270	-14 Reduced 2.5%	547 $6,000
Q1 2023 May 21, 2024	BUY	$12.53 - $21.71 $1,754 - $3,039	140 Added 33.25%	561 $7,000
Q1 2023 Apr 27, 2023	BUY	$12.53 - $21.71 $1,754 - $3,039	140 Added 33.25%	561 $8,000
Q4 2022 May 21, 2024	BUY	$11.61 - $16.11 $4,887 - $6,782	421 New	421 $5,000
Q4 2022 Jan 31, 2023	BUY	$11.61 - $16.11 $1,648 - $2,287	142 Added 50.9%	421 $5,000
Q3 2022 Oct 21, 2022	BUY	$12.21 - $19.7 $3,406 - $5,496	279 New	279 $4,000

Others Institutions Holding ICPT

# of Institutions

Shares Held

1.04M

Call Options Held

30K

Put Options Held

5.9K

View Full List

About INTERCEPT PHARMACEUTICALS, INC.

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

More about ICPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account